Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Non-Current Liabilities (2022 - 2024)

NewAmsterdam Pharma (NAMS) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $41.5 million as the latest value for Q3 2024.

  • Quarterly Total Non-Current Liabilities changed N/A to $41.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $41.5 million through Sep 2024, changed N/A year-over-year, with the annual reading at $50.9 million for FY2023, 330.18% up from the prior year.
  • Total Non-Current Liabilities hit $41.5 million in Q3 2024 for NewAmsterdam Pharma, down from $45.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $60.2 million in Q1 2024 to a low of $11.8 million in Q4 2022.
  • Historically, Total Non-Current Liabilities has averaged $42.1 million across 3 years, with a median of $45.9 million in 2024.
  • Biggest YoY gain for Total Non-Current Liabilities was 330.18% in 2023; the steepest drop was 330.18% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $11.8 million in 2022, then soared by 330.18% to $50.9 million in 2023, then dropped by 18.45% to $41.5 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for NAMS at $41.5 million in Q3 2024, $45.9 million in Q2 2024, and $60.2 million in Q1 2024.